Clinical Focus ›› 2021, Vol. 36 ›› Issue (2): 179-183.doi: 10.3969/j.issn.1004-583X.2021.02.017
Previous Articles Next Articles
-
Received:2020-08-15Online:2021-02-20Published:2021-02-05
CLC Number:
Cite this article
share this article
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.02.017
| [1] | World Health Organization. Global tuberculosis report 2019[R]. Geneva:WHO, 2019: 18-20. |
| [2] |
Tiberi S, Buchanan R, Caminero JA, et al. The challenge of the new tuberculosis drugs[J]. Presse Med, 2017,46(2 Pt 2):e41-e51.
doi: 10.1016/j.lpm.2017.01.016 URL |
| [3] |
Yew WW, Chan DP, Chang KC, et al. How does metformin act as a host-directed agent in tuberculosis associated with diabetes mellitus?[J]. J Thorac Dis, 2020,12(3):1124-1126.
doi: 10.21037/jtd URL |
| [4] | Restrepo BI. Diabetes and Tuberculosis[J]. Microbiol Spectr, 2016,4(6):17-23. |
| [5] |
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic reviewof 13 observational studies[J]. PLoS Med, 2008,5(7):e152.
doi: 10.1371/journal.pmed.0050152 URL |
| [6] |
Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants[J]. Lancet, 2011,378(9785):31-40.
doi: 10.1016/S0140-6736(11)60679-X URL |
| [7] |
Alba-Loureiro TC, Munhoz CD, Martins JO, et al. Neutrophil function and metabolism in individuals with diabetes mellitus[J]. Braz J Med Biol Res, 2007,40(8):1037-1044.
pmid: 17665039 |
| [8] |
Kumar Nathella P, Babu S. Influence of diabetes mellitus on immunity to human tuberculosis[J]. Immunology, 2017,152(1):13-24.
doi: 10.1111/imm.12762 pmid: 28543817 |
| [9] |
Lin CH, Kuo SC, Hsieh MC, et al. Effect of diabetes mellitus on risk of latent TB infection in a high TB incidence area: a community-based study in Taiwan[J]. BMJ Open, 2019,9(10):e029948.
doi: 10.1136/bmjopen-2019-029948 URL |
| [10] |
Ogbera AO, Kapur A, Abdur-Razzaq H, et al. Clinical profile of diabetes mellitus in tuberculosis[J]. BMJ Open Diabetes Res Care, 2015,3(1):e000112.
doi: 10.1136/bmjdrc-2015-000112 URL |
| [11] |
Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review[J]. BMC Med, 2011,9:81.
doi: 10.1186/1741-7015-9-81 URL |
| [12] | Ottmani SE, Murray MB, Jeon CY, et al. Consultation meeting on tuberculosis and diabetes mellitus: meeting summary and recommendations[J]. Int J Tuberc Lung Dis, 2010,14(12):1513-1517. |
| [13] |
Novita BD. Metformin: A review of its potential as enhancer for anti tuberculosis efficacy in diabetes mellitus-tuberculosis coinfection patients[J]. Indian J Tuberc, 2019,66(2):294-298.
doi: 10.1016/j.ijtb.2019.02.013 URL |
| [14] |
Rodriguez-Carlos A, Valdez-Miramontes C, Marin-Luevano P, et al. Metformin promotes mycobacterium tuberculosis killing and increases the production of human β-defensins in lung epithelial cells and macrophages[J]. Microbes Infect, 2020,22(3):111-118.
doi: 10.1016/j.micinf.2019.10.002 URL |
| [15] | Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy[J]. Sci Transl Med, 2014, 6(263):263ra159. |
| [16] |
Bachmakov I, Glaeser H, Fromm MF, et al. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1[J]. Diabetes, 2008,57(6):1463-1469.
doi: 10.2337/db07-1515 pmid: 18314419 |
| [17] |
Magee MJ, Salindri AD, Kornfeld H, et al. Reduced prevalence of latent tuberculosis infection in diabetes patients using metformin and statins[J]. Eur Respir J, 2019,53(3):1801695.
doi: 10.1183/13993003.01695-2018 URL |
| [18] |
Lee MC, Chiang CY, Lee CH, et al. Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: a nationwide cohort study with validated diagnostic criteria[J]. PLoS One, 2018,13(10):e0205807.
doi: 10.1371/journal.pone.0205807 URL |
| [19] |
Zhang M, He JQ. Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2020,76(2):149-159.
doi: 10.1007/s00228-019-02786-y pmid: WOS:000499562800001 |
| [20] |
Zhang C, Yang L, Zhao N, et al. Insights into macrophage autophagy in latent tuberculosis infection: role of heat shock protein 16.3[J]. DNA Cell Biol, 2018,37(5):442-448.
doi: 10.1089/dna.2017.4066 URL |
| [21] | Ernst JD. The immunological life cycle of tuberculosis[J]. Nat Rev Immunol, 2012,12(8):581-591. |
| [22] |
Zhuang Y, Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells[J]. Mol Cancer Res, 2011,9(5):603-615.
doi: 10.1158/1541-7786.MCR-10-0343 URL |
| [23] |
Novita BD, Ali M, Pranoto A, et al. Metformin induced autophagy in diabetes mellitus - tuberculosis co-infection patients: A case study[J]. Indian J Tuberc, 2019,66(1):64-69.
doi: 10.1016/j.ijtb.2018.04.003 URL |
| [24] |
Matsuzawa-Ishimoto Y, Hwang S, Cadwell K. Autophagy and inflammation[J]. Annu Rev Immunol, 2018,36:73-101.
doi: 10.1146/annurev-immunol-042617-053253 URL |
| [25] |
Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases[J]. Clin Interv Aging, 2018,13:757-772.
doi: 10.2147/CIA.S158513 pmid: 29731617 |
| [26] |
Choudhury G, MacNee W. Role of inflammation and oxidative stress in the pathology of ageing in COPD: potential therapeutic interventions[J]. COPD, 2017,14(1):122-135.
doi: 10.1080/15412555.2016.1214948 pmid: 27624918 |
| [27] |
Shastri MD, Shukla SD, Chong WC, et al. Role of oxidative stress in the pathology and management of human tuberculosis[J]. Oxid Med Cell Longev, 2018,2018:7695364.
doi: 10.1155/2018/7695364 pmid: 30405878 |
| [28] | Yilmaz B, Sucak A, Kilic S, et al. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, matrix metalloproteinase-9[J]. Am J Obstet Gynecol, 2010, 202(4):368.e1-368.e3688.. |
| [29] |
Unissa AN, Subbian S, Hanna LE, et al. Overview on mechanisms of isoniazid action and resistance in mycobacterium tuberculosis[J]. Infect Genet Evol, 2016,45:474-492.
doi: 10.1016/j.meegid.2016.09.004 URL |
| [30] |
Cakir E, Torun E, Gedik AH, et al. Cathelicidin and human β-defensin 2 in bronchoalveolar lavage fluid of children with pulmonary tuberculosis[J]. Int J Tuberc Lung Dis, 2014,18(6):671-675.
doi: 10.5588/ijtld.13.0831 URL |
| [31] |
Arai M, Uchiba M, Komura H, et al. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro[J]. J Pharmacol Exp Ther, 2010,334(1):206-213.
doi: 10.1124/jpet.109.164970 URL |
| [32] |
Lachmandas E, Eckold C, Böhme J, et al. Metformin alters human host responses to mycobacterium tuberculosis in healthy subjects[J]. J Infect Dis, 2019,220(1):139-150.
doi: 10.1093/infdis/jiz064 pmid: 30753544 |
| [33] |
Kumar A, Alam A, Grover S, et al. Peptidyl-prolyl isomerase-B is involved in mycobacterium tuberculosis biofilm formation and a generic target for drug repurposing-based intervention[J]. NPJ Biofilms Microbiomes, 2019,5:3.
doi: 10.1038/s41522-018-0075-0 URL |
| [34] |
Brindha S, Sundaramurthi JC, Velmurugan D, et al. Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB[J]. Bioinformation, 2016,12(8):359-367.
doi: 10.6026/bioinformation URL |
| [35] |
Caner S, Nguyen N, Aguda A, et al. The structure of the mycobacterium smegmatis trehalose synthase reveals an unusual active site configuration and acarbose-binding mode[J]. Glycobiology, 2013,23(9):1075-1083.
doi: 10.1093/glycob/cwt044 pmid: 23735230 |
| [36] |
Guirado E, Rajaram MV, Chawla A, et al. Deletion of PPARγ in lung macrophages provides an immunoprotective response against M. tuberculosis infection in mice[J]. Tuberculosis (Edinb), 2018,111:170-177.
doi: S1472-9792(18)30191-4 pmid: 30029904 |
| [37] |
Arnett E, Weaver AM, Woodyard KC, et al. PPARγ is critical for mycobacterium tuberculosis induction of Mcl-1 and limitation of human macrophage apoptosis[J]. PLoS Pathog, 2018,14(6):e1007100.
doi: 10.1371/journal.ppat.1007100 URL |
| [38] |
Lin SY, Tu HP, Lu PL, et al. Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes[J]. Respirology, 2018,23(11):1063-1073.
doi: 10.1111/resp.13338 URL |
| [39] |
Tseng CH. Metformin decreases risk of tuberculosis infection in type 2 diabetes patients[J]. J Clin Med, 2018,7(9):264.
doi: 10.3390/jcm7090264 URL |
| [40] |
Marupuru S, Senapati P, Pathadka S, et al. Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility[J]. Braz J Infect Dis, 2017,21(3):312-316.
doi: 10.1016/j.bjid.2017.01.001 URL |
| [41] | Lin KH, Luo CW, Chen SP, et al. α-Glucosidase inhibitor can effectively inhibit the risk of tuberculosis in patients with diabetes: a nested case-control study[J]. Biomed Res Int, 2020,2020:8085106. |
| [42] |
Degner NR, Wang JY, Golub JE, et al. Metformin use reverses the increased mortality associated With diabetes mellitus during tuberculosis treatment[J]. Clin Infect Dis, 2018,66(2):198-205.
doi: 10.1093/cid/cix819 URL |
| [43] |
Ma Y, Pang Y, Shu W, et al. Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up[J]. Eur J Clin Microbiol Infect Dis, 2018,37(7):1259-1263.
doi: 10.1007/s10096-018-3242-6 URL |
| [44] |
Lee YJ, Han SK, Park JH, et al. The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus[J]. Korean J Intern Med, 2018,33(5):933-940.
doi: 10.3904/kjim.2017.249 URL |
| [45] | 王淑霞, 杜亚东, 马艳, 等. 二甲双胍对复治肺结核并发糖尿病患者的疗效初探[J]. 中国防痨杂志, 2017,39(5):476-481. |
| [46] |
Sullivan T, Ben Amor Y. The co-management of tuberculosis and diabetes: challenges and opportunities in the developing world[J]. PLoS Med, 2012,9(7):e1001269.
doi: 10.1371/journal.pmed.1001269 URL |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||